• Qingqing Liu, Xi Huang, Mingyang Tian, Xiaoming Dong, Jinhua Kang, Huili Liao, Jianhong Liu, Yan Ling, Wenjie Long, and Zhongqi Yang.
• The First Clinical Medical College.
• Medicine (Baltimore). 2020 Dec 18; 99 (51): e23759e23759.

BackgroundXinyin Tablet (XYT) has been widely used in the treatment of CHF, Which helping to improve the clinical symptoms, enhance exercise, and even may improve the long-term prognosis of patients. However, the exact effectiveness and safety of XYT for CHF has not be comprehensively researched, so we want to generalize the effectiveness and safety of XYT for CHF through the meta-analysis, which may benefit the design of future clinical trials and provide valuable references.MethodsThis protocol complies with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols. From the inception until September 2020, a systematic and comprehensive electronic search about Relevant randomized controlled trials will be conducted in 4 English literature databases and 4 Chinese literature databases. The registration number: INPLASY2020100015. 2 investigators will be arranged to deal with the study selection and data extraction independently. The New York Heart Function Classification, traditional Chinese medicine (TCM) symptom scores, the scores of quality of life, 6-min walk distance (6MWD), etc. will be systematically measured as outcomes. At last, the data will be handled by Review Manager 5.3 and Stata 15.0.Results And ConclusionThis study is hoping to provide a high-level evidence to prove the therapeutic effect of XYT on CHF, which may enhance the application of Chinese medicine.Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

39 keywords...

hide…